N. prodotti: 0
Totale ordine: € 0,00
A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413
Stefano A. 1, 2, Gallivanone F. 1, Messa C. 1, 2, 3, 4, Gilardi M. C. 1, 3, 5, Castiglioni I. 1
1 Institute for Molecular Bioimaging and Physiology (IBFM), National Research Council (CNR), Cefalù‑Segrate, Cefalù, Palermo, Italy;
2 Laboratorio di Tecnologie Oncologiche (LATO), HSR G. Giglio, Cefalù, Palermo, Italy;
3 Department of Health Sciences, University of Milano‑Bicocca, Milan, Italy;
4 Nuclear Medicine Center, San Gerardo Hospital Monza, Monza e Brianza, Italy;
5 Department of Nuclear Medicine, Scientific Institute H. S. Raffaele, Milan, Italy
AIM: The aim of this work is to evaluate the metabolic impact of Partial Volume Correction (PVC) on the measurement of the Standard Uptake Value (SUV) from [18F]FDG PET-CT oncological studies for treatment monitoring purpose.
METHODS: Twenty-nine breast cancer patients with bone lesions (42 lesions in total) underwent [18F]FDG PET-CT studies after surgical resection of breast cancer primitives, and before (PET-I) and after (PET-II) chemotherapy and hormone treatment. PVC of bone lesion uptake was performed on the two [18F]FDG PET-CT studies, using a method based on Recovery Coefficients (RC) and on an automatic measurement of lesion metabolic volume. Body-weight average SUV was calculated for each lesion, with and without PVC. The accuracy, reproducibility, clinical feasibility and the metabolic impact on treatment response of the considered PVC method was evaluated.
RESULTS: The PVC method was found clinically feasible in bone lesions, with an accuracy of 93% for lesion sphere-equivalent diameter >1 cm. Applying PVC, average SUV values increased, from 7% up to 154% considering both PET-I and PET-II studies, proving the need of the correction. As main finding, PVC modified the therapy response classification in 6 cases according to EORTC 1999 classification and in 5 cases according to PERCIST 1.0 classification.
CONCLUSION: PVC has an important metabolic impact on the assessment of tumor response to treatment by [18F]FDG PET-CT oncological studies.